SA515360981B1 - مُعدِّلات بيريميدين بنزوإيميدازول-2-يل لمستقبِل الهستامين h4 - Google Patents
مُعدِّلات بيريميدين بنزوإيميدازول-2-يل لمستقبِل الهستامين h4 Download PDFInfo
- Publication number
- SA515360981B1 SA515360981B1 SA515360981A SA515360981A SA515360981B1 SA 515360981 B1 SA515360981 B1 SA 515360981B1 SA 515360981 A SA515360981 A SA 515360981A SA 515360981 A SA515360981 A SA 515360981A SA 515360981 B1 SA515360981 B1 SA 515360981B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- tetrahydrate
- methyl
- hemitartrate
- compound
- tartrate
- Prior art date
Links
- WTZRQYJHRXQWTK-UHFFFAOYSA-N 2-pyrimidin-2-yl-1h-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1C1=NC=CC=N1 WTZRQYJHRXQWTK-UHFFFAOYSA-N 0.000 title abstract 2
- 102000004187 Histamine H4 receptors Human genes 0.000 title 1
- 108090000796 Histamine H4 receptors Proteins 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 8
- 230000000694 effects Effects 0.000 claims abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 6
- 201000010099 disease Diseases 0.000 claims abstract 2
- JJXABLRAISJPTN-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid octahydrate Chemical compound O.O.O.O.O.O.O.O.OC(C(O)C(O)=O)C(O)=O JJXABLRAISJPTN-UHFFFAOYSA-N 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 10
- 239000012535 impurity Substances 0.000 claims 6
- 102000000543 Histamine Receptors Human genes 0.000 claims 5
- 108010002059 Histamine Receptors Proteins 0.000 claims 5
- 238000002441 X-ray diffraction Methods 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 150000004685 tetrahydrates Chemical class 0.000 claims 5
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- DYKCZVHJLMDZEP-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid tetrahydrate Chemical compound O.O.O.O.OC(=O)C(O)C(O)C(O)=O DYKCZVHJLMDZEP-UHFFFAOYSA-N 0.000 claims 3
- IEQHWSWDQPNZTK-UHFFFAOYSA-N 3-(1-methylpiperidin-4-yl)propan-1-amine Chemical compound CN1CCC(CCCN)CC1 IEQHWSWDQPNZTK-UHFFFAOYSA-N 0.000 claims 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 2
- 229940095064 tartrate Drugs 0.000 claims 2
- -1 tetrahydrate Salt Chemical class 0.000 claims 2
- 241001124076 Aphididae Species 0.000 claims 1
- 241000726103 Atta Species 0.000 claims 1
- 241000219495 Betulaceae Species 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 claims 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N N-methylcyclohexylamine Natural products CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 claims 1
- 229940037003 alum Drugs 0.000 claims 1
- YSXKPIUOCJLQIE-UHFFFAOYSA-N biperiden Chemical compound C1C(C=C2)CC2C1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 YSXKPIUOCJLQIE-UHFFFAOYSA-N 0.000 claims 1
- 229940126214 compound 3 Drugs 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims 1
- 238000000034 method Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000003251 Pruritus Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
- C30B29/54—Organic compounds
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
- C30B7/08—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by cooling of the solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
يتعلق هذا الاختراع ببنزإيميدازول-2-يل بيريميدينات benzoimidazol-2-yl pyrimidines وطرق تنقيتها وتركيبات صيدلانية وطرق للحصول لمعالجة حالات مرضية واضطرابات وحالات تحدث نتيجة لنشاط مستقبل الهستامين H4، بما في ذلك الحساسية allergy والربو asthma وأمراض المناعة الذاتية autoimmune diseases والحكة pruritus.
Claims (1)
- —qy— عناصر الحماية SLT ل ]© ) ؛ hemitartrate ~~ tetrahydrate ملح نصف طرطرات رباعي هيدرات 5 - 4 - -يل] -[7-(١-ميثيل -بيبيريدين Yo -ميثيل -بيريميدين 4 (do 7 - -بنزوإيميدازول TH- ميثيل [5-(4,6-Dimethyl- 1 H-benzoimidazol-2-y)-4- methyl pyrimidin-2-y1J- يل)-بروبيل]-أمين بالصيغة التالية: [3-(1-methyl-piperidin-4-yl)-propyl]-amine ~ Ay tri ص N N * 05 He pen * 4H,0 } HO.C OH 5 وفقاً لعنصر الحماية رقم hemitartrate tetrahydrate ملح نصف طرطرات رباعي هيدرات LY حيث تتضمن الصورة العامة لحيود الأشعة السينية لنصف طرطرات رباعي هيدرات ١ المذكور القمم التالية: hemitartrate tetrahydrate — وفقاً لعنصر الحماية رقم hemitartrate tetrahydrate ملح نصف طرطرات رباعي هيدرات LF حيث تتضمن الصورة العامة لحيود الأشعة السينية لنصف طرطرات رباعي هيدرات ١ ٠ المذكور القمم التالية: hemitartrate tetrahydrate ** 000 لاخغةA وفقاً لعنصر الحماية رقم hemitartrate tetrahydrate ملح نصف طرطرات رباعي هيدرات Lf حيث تتضمن الصورة العامة لحيود الأشعة السينية لنصف طرطرات رباعي هيدرات ١ المذكور القمم التالية: hemitartrate tetrahydrate تا tARY qa وفقاً لعنصر الحماية رقم hemitartrate tetrahydrate ملح نصف طرطرات رباعي هيدرات 0 حيث تتضمن الصورة العامة لحيود الأشعة السينية لنصف طرطرات رباعي هيدرات ١ المذكور القمم التالية: hemitartrate tetrahydrate I وفقاً لعنصر الحماية رقم hemitartrate tetrahydrate ملح نصف طرطرات رباعي هيدرات 1 حيث تتضمن الصورة العامة لحيود الأشعة السينية لنصف طرطرات رباعي هيدرات ١ المذكور القمم التالية: hemitartrate tetrahydrate tARYا — — —اخلط-"١7١- تركيبة صيدلانية لعلاج مرض» اضطراب؛ أو حالة طبية يسببها نشاط مستقبل الهستامين LV .١ بل متضمنة كمية فعالة من مركب واحد على الأقل كما هو مذكور في عنصر الحماية رقم يئانث-٠١ ¢)=0] ل hemitartrate tetrahydrate ملح نصف طرطرات رباعي هيدرات A - -ميثيل “بيبيريدين -؛ ١ (-7[- -يل] Yo -بنزوايميدازول - ؟ -يل) -4 -ميثيل “بيريميدين THE ميثيل 5-(4,6- Dimethyk 1H-benzoimidazol- 2-y))-4-methyk pyrimidin-2-yll- يل)-بروبيل] -أمين © بالصيغة: [3-(1-methyl-piperidin-4-yl)-propyl]-amine ON “الى م مار 2 a \ J H 2 5 HO, FOR, 4H,0 . H odo المذكور لا يحتوي فعلياً على hemitartrate tetrahydrate حيث أن نصف طرطرات رباعي هيدرات الأقل على الشوائب 11+13 و18 بالصيغ: tARY= N— 2 " yt ا يبا ل يل )3( 011 MN نار مل لمي وض يرا الم 84 {i8) . بت ملح نصف طرطرات رباعي هيدرات hemitartrate tetrahydrate من SUT c£)=0] ميثيل -111 -بنزوايميدازول - ؟ (da -ميثيل “بيريميدين - 7 -يل] ١(-[- -ميثيل “بيبيريدين = - (J -بروبيل] -أمين Ga, لعنصر الحماية A حيث يكون ملح نصف طرطرات ربا عي هيدرات tetrahydrate © عنمتمشضه» _المذكور Ud WA على الأقل من شائبة 15 بالصيغة: ass ضحد ا كر إل NNN SNH 7 ٍ] ا he داف ند > She H H N ag ~~ a5).٠ ملح نصف طرطرات رباعي هيدرات hemitartrate tetrahydrate من ]0=)£ Se ميثيل -111 -بنزوايميدازول - ؟ (da -ميثيل “بيريميدين - 7 -يل] ١(-[- -ميثيل “بيبيريدين = - يل)-بروبيل] -أمين -زارٍ-2-متةتمترم Dimethyk 1H-benzoimidazol- 2-y))-4-methyk -4,6(-5 [3-(1-methyl-piperidin-4-yl)-propyl]-amine ~~ ٠ وفقًا لعنصر الحماية 4 حيث لا يحتوي ملح نصف طرطرات رباعي هيدرات hemitartrate tetrahydrate المذكور على أكثر من 960,7 من شائبة 7 ات الصيغة: va \ 1 a .2 NH ما بل an) إ: اخلط_ 7 Ad —_ Se £)=0] من hemitartrate tetrahydrate ملح تنصف طرطرات رباعي هيدرات .١١ ميثيل THE -بنزوايميدازول - ؟ (J -4 -ميثيل “بيريميدين Yo -يل] -[7-( ١ -ميثيل “بيبيريدين = - 5-(4,6- Dimethyl 1H-benzoimidazol-2- y) -4-methyk pyrimidin-2-ylJ- يل)-بروبيل]-أمين عمتصة-[1ترم 10م [3-(1-methyl-piperidin-4- yl)- وفقًا لعنصر الحماية Ve حيث لا يحتوي ملح © نصف طرطرات رباعي هيدرات hemitartrate tetrahydrate المذكور على أكثر من 9600036 من شائبة 7 ات الصيغة: Nt ؤ L 8 N an 0 N= )07 :.١" تركيبة صيدلانية لعلاج (age اضطراب؛ أو Alla طبية يسببها نشاط مستقبل الهستامين Ady متضمنة كمية فعالة من مركب واحد على الأقل كما هو مذكور في عنصر الحماية Hy اضطراب؛ أو حالة طبية يسببها نشاط مستقبل الهستامين (ape تركيبة صيدلانية لعلاج NT).9 متضمنة كمية فعالة من مركب واحد على الأقل كما هو مذكور في عنصر الحماية رقم Hy64. تركيبة صيدلانية لعلاج (age اضطراب؛ أو Alla طبية يسببها نشاط مستقبل الهستامين بل متضمنة كمية فعالة من مركب واحد على الأقل كما هو مذكور في عنصر الحماية رقم .٠١ WYO تركيبة صيدلانية لعلاج «(gage اضطراب؛ أو Alla طبية يسببها نشاط مستقبل الهستامين (Hy ٠ متضمنة كمية فعالة من مركب واحد على الأقل كما هو مذكور في عنصر الحماية رقم AY tARYا شكل ١ 3 ل[ 1 1[ ١ FT J ١ ] HT YA TAT TY TYEE RE Ye TRY اج للع أ نرم كدح الالحية بط ror ني Toba Uw Zing \ [2g 2 اخلطاج 7 _ شكل ؟ مك ى .سس عا ناا ره — اا ااا اذا hl% | vy ¥ 1 في العيثة ee A 3 — : Ph oh ال ل 0 ا TT Lie 0 0 ا ب امسا الها ؤ A NY + تح بح ABT 0 hs Nl A 8 حم اح APHID ل % / 28 السكسب .1 لان I سالا i و رحب i I = 1 » I yoy Te va] 4 ] م Abid 0 المركب 3ن المركب ؟ tARYI< = ؟ 8 اتا لمحتتال 0 1 س1 مم م١ سس ا ! اس ا ا A و * 96 الشواتب A ay ِ 1 5 — 0 ,في العينة mn تفن NA: I i = wy be \ 7 ——— 1 ات Sr ب ال 1 جا ا EE rs _ Nt 5 > . AN 2% 70 يذ حر اح اد ٍ 1 I Y - I 1 1 ححا م 1 3 I oe I = 1 اانه ٠ A= I 1 سالا EA الشاتبة 1[ المركب Al المركب YY tARYل ١ شكل ؛ Vo ا ام فم Ki RE 3 7 i EIEN BY ض 2 ! man! م دا لان سا مط pub SA A ساسالا لاا اال إ: لب ' ! oS صفر د له 7 68 *) Of. يجي يخ # .6 YR ذة )ع ff + + Se AY RE AT vA Yer daly 2 614 م١ درجةٌ tARYشكل o ان حم إ إ (_ د د اا لصب _ سس . 1 2 ory 1 '' % الشوائب ...ص ناا لاس . “salt — ا 7 في العيئة bo i 3 ! yy ا NRE ١ دا ار ان ; مالي الصا RY) ٍِ : 1 .مها I _ 1" | ~~ TY, Ly دج ¥Y=1 so 1و ]حو احم الشائبة ل المركبة ء ْنا المركب ؟ لاخغةq — 7 _ شكل 4١. ل صفر tat v ¥ ٠ مليغرام .( RANE : \ vor إ ٠١ جول/غرام ا -— \ 3 A%re,v. 3 4 53 77 مليغرام = ns 4 5 : 0 3 x | | سا؟ AN Ao : لبجم ال نا الا لاسا لاا ااانه اتات ااانا الا اناا افا ااانا ع FICS 6 Veo Va Yo Yeo AE درجة الحرارة ("متوية) EASY_ A «= AE We fd Vy BAY, AY i io مليغرام) 101 0A) FY i Cay, ve i 1 0 alder — Nr ra = : fo JT ما : 1 — « 3 ! 9h Y.v =, 4 8 a i Ne J 3 3 ااا ِ A » = : : ١ ما : 0 ا ا a yeo— av.Lo صغر J LRN A= You Yao. بو درجة الحرارة ("مثوية) لاخ-أ0- AJ م به BY 0 A & 3 | ا Foals SPR So Nowe : صقر VTA, VA | Fae = ١ ٍ Pe , A | 9 2 أ 3 3 A Q shelly A 0 7 + أ 59 ع > 3 re SANE Lg 3 برق م ؟ ا «طاضم ENCE TRA \ | 2 2 حب | o §& = x ١ = ب yy, eof VEL 3 j “ | = AN | A x / 1 Yo Fve vos Vo. ل١ & Yo. a + 3 وت صفر درجة الحرازة (fae) اخلط17d0. 1 : 1 : ; EI i 5 8 YER ةيا كيلا | اله “| التمانة صل رزان الب ل | ! i TesFir. | ER I 0 PARE از ا يي it 1 1 بأ أ 4 0 | il 1 0 a إل 0 ب ل ل ال i Cn ef eth Tse أ : ا J | 1 لقدا:__ررسراسة لطا N WARY Fa 1 7 1 1 1 ALI A 1 ١ ¥ TN 1 0 0 be ts ¥, ينا wide اخلطمدة سريان هذه البراءة عشرون سنة من تاريخ إيداع الطلب وذلك بشرط تسديد المقابل المالي السنوي للبراءة وعدم بطلانها أو سقوطها لمخالفتها لأي من أحكام نظام براءات الاختراع والتصميمات التخطيطية للدارات المتكاملة والأصناف النباتية والنماذج الصناعية أو لائحته التنفيذية صادرة عن مدينة الملك عبدالعزيز للعلوم والتقنية ؛ مكتب البراءات السعودي ص ب TAT الرياض 57؟؟١١ ¢ المملكة العربية السعودية بريد الكتروني: patents @kacst.edu.sa
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361773706P | 2013-03-06 | 2013-03-06 | |
US201361776260P | 2013-03-11 | 2013-03-11 | |
US201361784909P | 2013-03-14 | 2013-03-14 | |
PCT/US2014/021130 WO2014138368A1 (en) | 2013-03-06 | 2014-03-06 | Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
SA515360981B1 true SA515360981B1 (ar) | 2016-06-23 |
Family
ID=51488591
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SA515360981A SA515360981B1 (ar) | 2013-03-06 | 2015-09-03 | مُعدِّلات بيريميدين بنزوإيميدازول-2-يل لمستقبِل الهستامين h4 |
Country Status (38)
Country | Link |
---|---|
US (4) | US8859575B2 (ar) |
EP (2) | EP3660011A1 (ar) |
JP (1) | JP6471103B2 (ar) |
KR (1) | KR102230383B1 (ar) |
CN (1) | CN105025898B (ar) |
AU (1) | AU2014225675B2 (ar) |
BR (1) | BR112015021463A8 (ar) |
CA (1) | CA2903737C (ar) |
CL (1) | CL2015002434A1 (ar) |
CR (1) | CR20150435A (ar) |
CY (1) | CY1122545T1 (ar) |
DK (1) | DK2964229T3 (ar) |
DO (1) | DOP2016000027A (ar) |
EA (1) | EA201591648A1 (ar) |
ES (1) | ES2773543T3 (ar) |
GT (1) | GT201500243A (ar) |
HK (1) | HK1218513A1 (ar) |
HR (1) | HRP20200253T1 (ar) |
HU (1) | HUE047681T2 (ar) |
IL (1) | IL240247B (ar) |
JO (1) | JO3516B1 (ar) |
LT (1) | LT2964229T (ar) |
MX (1) | MX2015011688A (ar) |
MY (1) | MY180726A (ar) |
NZ (1) | NZ710640A (ar) |
PE (1) | PE20151536A1 (ar) |
PH (1) | PH12015501731A1 (ar) |
PL (1) | PL2964229T3 (ar) |
PT (1) | PT2964229T (ar) |
RS (1) | RS59909B1 (ar) |
SA (1) | SA515360981B1 (ar) |
SG (1) | SG11201507117XA (ar) |
SI (1) | SI2964229T1 (ar) |
TW (1) | TWI617554B (ar) |
UA (1) | UA118754C2 (ar) |
UY (1) | UY35370A (ar) |
WO (1) | WO2014138368A1 (ar) |
ZA (1) | ZA201507351B (ar) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2648036C (en) | 2006-03-31 | 2012-05-22 | Janssen Pharmaceutica N.V. | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor |
US9371311B2 (en) | 2008-06-30 | 2016-06-21 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidine derivatives |
UY35370A (es) | 2013-03-06 | 2014-09-30 | Janssen Pharmaceutica Nv | Moduladores benzoimidazol-2-il pirimidina del receptor de histamina h4 |
WO2014152537A1 (en) | 2013-03-14 | 2014-09-25 | Janssen Pharmaceutica Nv | P2x7 modulators |
TWI627174B (zh) | 2013-03-14 | 2018-06-21 | 比利時商健生藥品公司 | P2x7調控劑 |
JO3773B1 (ar) | 2013-03-14 | 2021-01-31 | Janssen Pharmaceutica Nv | معدلات p2x7 |
EP2970271B1 (en) | 2013-03-14 | 2017-11-08 | Janssen Pharmaceutica NV | P2x7 modulators |
ES2714048T3 (es) | 2014-09-12 | 2019-05-24 | Janssen Pharmaceutica Nv | Moduladores de P2X7 |
JP6827113B2 (ja) | 2017-01-21 | 2021-02-10 | 広州白雲山漢方現代薬業有限公司Guangzhou Hanfang Pharmaceutical Co.,Ltd. | シェーグレン症候群の治療におけるペオニフロリン−6’−o−ベンゼンスルホン酸の使用 |
EP3856179A1 (en) | 2018-09-28 | 2021-08-04 | Janssen Pharmaceutica N.V. | Monoacylglycerol lipase modulators |
EP3856178A1 (en) | 2018-09-28 | 2021-08-04 | Janssen Pharmaceutica NV | Monoacylglycerol lipase modulators |
US11839663B2 (en) | 2019-09-30 | 2023-12-12 | Janssen Pharmaceutica Nv | Radiolabelled MGL pet ligands |
JP2023518511A (ja) | 2020-03-26 | 2023-05-01 | ヤンセン ファーマシューティカ エヌ.ベー. | モノアシルグリセロールリパーゼ調節因子 |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3005852A (en) | 1959-12-22 | 1961-10-24 | Gen Aniline & Film Corp | Production of sulfoxides and sulfones |
GB1062357A (en) | 1965-03-23 | 1967-03-22 | Pfizer & Co C | Quinazolone derivatives |
US3931195A (en) | 1971-03-03 | 1976-01-06 | Mead Johnson & Company | Substituted piperidines |
US4191828A (en) | 1976-04-14 | 1980-03-04 | Richardson-Merrell Inc. | Process for preparing 2-(2,2-dicyclohexylethyl)piperidine |
US4337341A (en) | 1976-11-02 | 1982-06-29 | Eli Lilly And Company | 4a-Aryl-octahydro-1H-2-pyrindines |
US4190601A (en) | 1978-05-31 | 1980-02-26 | Union Carbide Corporation | Production of tertiary amines by reductive alkylation |
JPS6130576A (ja) | 1984-07-24 | 1986-02-12 | Ube Ind Ltd | 2−アミノ−5−シアノピリミジンの製法 |
GB9410031D0 (en) | 1994-05-19 | 1994-07-06 | Merck Sharp & Dohme | Therapeutic agents |
GB9422391D0 (en) | 1994-11-05 | 1995-01-04 | Solvay Interox Ltd | Oxidation of organosulphur compounds |
JPH10510540A (ja) | 1994-12-12 | 1998-10-13 | オメロス メディカル システムズ,インコーポレーテッド | 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法 |
EP0891351A1 (en) | 1996-04-03 | 1999-01-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5883105A (en) | 1996-04-03 | 1999-03-16 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5880140A (en) | 1996-04-03 | 1999-03-09 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
WO1997036898A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5939439A (en) | 1996-12-30 | 1999-08-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1998031369A1 (fr) | 1997-01-16 | 1998-07-23 | Sekisui Chemical Co., Ltd. | Preparations a usage externe a absorption percutanee |
CA2277273C (en) | 1997-01-17 | 2008-03-25 | Merck & Co., Inc. | Integrin antagonists |
US5945422A (en) | 1997-02-05 | 1999-08-31 | Warner-Lambert Company | N-oxides of amino containing pyrido 2,3-D! pyrimidines |
JP2001524079A (ja) | 1997-04-07 | 2001-11-27 | メルク エンド カンパニー インコーポレーテッド | ガンの治療方法 |
GB9801231D0 (en) | 1997-06-05 | 1998-03-18 | Merck & Co Inc | A method of treating cancer |
WO1999018079A1 (en) | 1997-10-06 | 1999-04-15 | Warner-Lambert Company | Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
ATE245641T1 (de) | 1998-02-17 | 2003-08-15 | Tularik Inc | Antivirale pyrimidinderivate |
JP4533534B2 (ja) | 1998-06-19 | 2010-09-01 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | グリコーゲンシンターゼキナーゼ3のインヒビター |
SI1038875T1 (en) | 1999-03-25 | 2003-12-31 | Synthon B.V. | Imidazopyridine derivatives and process for making them |
ATE301651T1 (de) | 1999-06-23 | 2005-08-15 | Aventis Pharma Gmbh | Substituierte benzimidazole |
TWI279402B (en) | 1999-08-20 | 2007-04-21 | Banyu Pharma Co Ltd | Spiro compounds having NPY antagonistic activities and agents containing the same |
YU23802A (sh) | 1999-09-30 | 2004-09-03 | Neurogen Corporation | Određeni alkilen diamin-supstituisani pirazolo/1,5-a/-1,5- piramidini i pirazolo/1,5-a/1,3,5-triazini |
TR200103147T1 (tr) | 1999-12-27 | 2002-06-21 | Japan Tobacco Inc. | Kaynaşık halkalı bileşikler ve bunların ilaç olarak kullanımı. |
DE10006453A1 (de) | 2000-02-14 | 2001-08-16 | Bayer Ag | Piperidylcarbonsäuren als Integrinantagonisten |
CN1592621A (zh) * | 2000-04-24 | 2005-03-09 | 特瓦制药工业有限公司 | 唑吡坦半酒石酸盐 |
YU79402A (sh) * | 2000-04-24 | 2006-03-03 | Teva Pharmaceutical Industries Ltd. | Zolpidem hemitartrat |
JP2004501913A (ja) | 2000-06-23 | 2004-01-22 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | ヘテロアリール−フェニル置換Xa因子阻害剤 |
EP1305401A2 (en) | 2000-06-28 | 2003-05-02 | Thromb-X N.V. | Pluripotent embryonic stem (es) cell lines, improved methods for their production, and their use for germ line transmission and for the generation of genetically modified animals |
IL153662A0 (en) | 2000-07-21 | 2003-07-06 | Syngenta Participations Ag | Process for the preparation of 4,6-dimethoxy-2- (methylsulfonyl)-1,3-pyrimidine |
AU2001295026B2 (en) | 2000-09-06 | 2008-04-03 | Novartis Vaccines And Diagnostics, Inc. | Inhibitors of glycogen synthase kinase 3 |
JP2004517074A (ja) | 2000-11-20 | 2004-06-10 | ファルマシア・コーポレーション | 凝血カスケードを選択的に阻害するのに有用な置換された多環アリールおよびヘテロアリールピリジン類 |
WO2002064096A2 (en) | 2001-02-16 | 2002-08-22 | Tularik Inc. | Methods of using pyrimidine-based antiviral agents |
EP1373204B1 (en) | 2001-03-09 | 2016-10-26 | Janssen Pharmaceuticals, Inc. | Heterocyclic compounds |
JP2004525139A (ja) | 2001-03-23 | 2004-08-19 | 中外製薬株式会社 | Flt−1リガンド、および血管形成により調節可能な疾患の治療におけるそれらの使用 |
JP2004525150A (ja) | 2001-03-30 | 2004-08-19 | スミスクライン ビーチャム コーポレーション | 治療用化合物としてのピラゾロピリジン類の使用 |
AU2002305450A1 (en) | 2001-05-08 | 2002-11-18 | Yale University | Proteomimetic compounds and methods |
AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
CN1585641A (zh) * | 2001-11-05 | 2005-02-23 | 默克专利有限公司 | 亚肼基-丙二腈化合物 |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
WO2003062235A1 (en) | 2002-01-17 | 2003-07-31 | Eli Lilly And Company | Modulators of acetylcholine receptors |
TWI270542B (en) | 2002-02-07 | 2007-01-11 | Sumitomo Chemical Co | Method for preparing sulfone or sulfoxide compound |
US7314937B2 (en) | 2002-03-21 | 2008-01-01 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses |
US7498349B2 (en) | 2002-08-02 | 2009-03-03 | Genesoft Pharmaceuticals, Inc. | Biaryl compounds having anti-infective activity |
CN1694703A (zh) | 2002-09-06 | 2005-11-09 | 詹森药业有限公司 | 吲哚基衍生物在制备治疗变应性鼻炎的药物中的用途 |
DK1543011T3 (da) | 2002-09-06 | 2006-08-07 | Janssen Pharmaceutica Nv | Thienopyrrolyl- og furanopyrrolylforbindelser og deres anvendelse som histamin H4-receptorligander |
US20040127395A1 (en) | 2002-09-06 | 2004-07-01 | Desai Pragnya J. | Use of histamine H4 receptor modulators for the treatment of allergy and asthma |
CA2497827A1 (en) | 2002-09-06 | 2004-03-18 | Janssen Pharmaceutica, N.V. | (1h-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine h4-receptor antagonists for the treatment of inflammatory and allergic disorders |
AU2003275242B2 (en) | 2002-09-27 | 2010-03-04 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
TW200501960A (en) | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
US20040105856A1 (en) | 2002-12-02 | 2004-06-03 | Robin Thurmond | Use of histamine H4 receptor antagonist for the treatment of inflammatory responses |
CN100372851C (zh) | 2003-05-05 | 2008-03-05 | 弗·哈夫曼-拉罗切有限公司 | 具有crf活性的稠合的嘧啶衍生物 |
AU2004247013B2 (en) | 2003-05-14 | 2010-07-08 | Neurogenetic Pharmaceuticals, Inc. | Compounds and uses thereof in modulating amyloid beta |
SE0302116D0 (sv) * | 2003-07-21 | 2003-07-21 | Astrazeneca Ab | Novel compounds |
WO2005039485A2 (en) | 2003-08-13 | 2005-05-06 | Chiron Corporation | Gsk-3 inhibitors and uses thereof |
US7781595B2 (en) | 2003-09-22 | 2010-08-24 | S*Bio Pte Ltd. | Benzimidazole derivatives: preparation and pharmaceutical applications |
JP2007507514A (ja) | 2003-09-30 | 2007-03-29 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | キノキサリン化合物 |
EP1673348B1 (en) | 2003-09-30 | 2009-04-01 | Janssen Pharmaceutica N.V. | Benzoimidazole compounds |
WO2005032490A2 (en) | 2003-10-08 | 2005-04-14 | Bristol-Myers Squibb Company | Cyclic diamines and derivatives as factor xa inhibitors |
US20070099938A1 (en) | 2003-10-24 | 2007-05-03 | Ono Pharmaceutical Co., Ltd. | Antistress drug and medical use thereof |
US8277831B2 (en) | 2004-02-17 | 2012-10-02 | Advanced Technologies And Regenerative Medicine, Llc. | Drug-enhanced adhesion prevention |
CN101022728B (zh) | 2004-03-25 | 2012-08-08 | 詹森药业有限公司 | 咪唑化合物 |
CN1960977B (zh) | 2004-05-31 | 2010-07-21 | 万有制药株式会社 | 喹唑啉衍生物 |
WO2006004791A1 (en) | 2004-06-30 | 2006-01-12 | Janssen Pharmaceutica, N.V. | Aryl-substituted benzimidazole and imidazopyridine ethers as anti-cancer agents |
US7718801B2 (en) | 2004-08-31 | 2010-05-18 | Banyu Pharmaceutical Co., Ltd. | Substituted imidazole derivative |
US7906528B2 (en) | 2004-10-05 | 2011-03-15 | Novartis International Pharmaceutical Ltd. | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds |
US7381732B2 (en) | 2004-10-26 | 2008-06-03 | Bristol-Myers Squibb Company | Pyrazolobenzamides and derivatives as factor Xa inhibitors |
US7442716B2 (en) | 2004-12-17 | 2008-10-28 | Merck Frosst Canada Ltd. | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors |
JP5086809B2 (ja) | 2004-12-17 | 2012-11-28 | メルク カナダ インコーポレイテッド | mPGES−1阻害剤としての2−(フェニルまたはヘテロ環式)−1H−フェナントロ[9,10−d]イミダゾール |
AU2006226775A1 (en) | 2005-03-24 | 2006-09-28 | Janssen Pharmaceutica, N.V. | Biaryl derived amide modulators of vanilloid VR1 receptor |
WO2007044085A2 (en) | 2005-05-19 | 2007-04-19 | Xenon Pharmaceuticals Inc. | Heteroaryl compounds and their uses as therapeutic agents |
JP5118029B2 (ja) | 2005-06-14 | 2013-01-16 | タイゲン バイオテクノロジー カンパニー,リミテッド | ピリミジン化合物 |
US8193206B2 (en) | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
AU2006264966B2 (en) | 2005-07-04 | 2013-02-21 | High Point Pharmaceuticals, Llc | Histamine H3 receptor antagonists |
BRPI0615880A2 (pt) | 2005-09-13 | 2011-05-31 | Palau Pharma Sa | compostos derivados de 2-aminopirimidina como moduladores da atividade de receptor da histamina h4, uso dos mesmos e composição farmacêutica |
AR056560A1 (es) | 2005-10-06 | 2007-10-10 | Astrazeneca Ab | Pirrolopiridinonas como moduladores cb1 |
WO2007070173A2 (en) | 2005-10-31 | 2007-06-21 | Merck & Co., Inc. | Cetp inhibitors |
WO2007063935A1 (ja) | 2005-12-02 | 2007-06-07 | Mitsubishi Tanabe Pharma Corporation | 芳香族化合物 |
AU2007218966A1 (en) | 2006-02-24 | 2007-08-30 | Merck Frosst Canada Ltd. | 2-(phenyl or heterocyclic) - 1h-phenanthro [9,10-d] imidazoles |
WO2007117400A2 (en) | 2006-03-31 | 2007-10-18 | Janssen Pharmaceutica N.V. | Benzoimidazol-2-yl pyridines as modulators of the histamine h4 receptor |
CA2648036C (en) | 2006-03-31 | 2012-05-22 | Janssen Pharmaceutica N.V. | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor |
CN101472584B (zh) | 2006-04-07 | 2013-04-24 | 詹森药业有限公司 | 用作组胺h4受体调节剂的吲哚类和苯并咪唑类 |
US20090069343A1 (en) | 2006-04-10 | 2009-03-12 | Dunford Paul J | Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus |
EP2019675A4 (en) | 2006-05-02 | 2011-03-02 | Merck Frosst Canada Ltd | METHODS FOR TREATING OR PREVENTING NEOPLASIA |
US20090209571A1 (en) | 2006-05-18 | 2009-08-20 | Bernard Cote | Phenanthrene derivatives as MPGES-1 inhibitors |
EA015344B1 (ru) | 2006-07-11 | 2011-06-30 | Янссен Фармацевтика, Н.В. | Бензофуро- и бензотиенопиримидиновые модуляторы гистаминового рецептора н |
US8779154B2 (en) * | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
CL2008000467A1 (es) | 2007-02-14 | 2008-08-22 | Janssen Pharmaceutica Nv | Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma |
WO2009068512A1 (en) | 2007-11-30 | 2009-06-04 | Palau Pharma, S. A. | 2 -amino-pyrimidine derivatives as histamine h4 antagonists |
US8084466B2 (en) | 2007-12-18 | 2011-12-27 | Janssen Pharmaceutica Nv | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor |
US8841287B2 (en) | 2008-06-12 | 2014-09-23 | Janssen Pharmaceutica N.V. | Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor |
JP5658661B2 (ja) | 2008-06-12 | 2015-01-28 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap | 手術後癒着の治療のためのヒスタミンh4拮抗物質の使用 |
CN102137857A (zh) * | 2008-06-30 | 2011-07-27 | 詹森药业有限公司 | 用于制备苯并咪唑-2-基嘧啶衍生物的方法 |
MX2011000080A (es) | 2008-06-30 | 2011-03-02 | Janssen Pharmaceutica Nv | Proceso para la preparacion de derivados de pirimidina sustituidos. |
US8852569B2 (en) | 2008-08-28 | 2014-10-07 | The General Hospital Corporation | Prevention and treatment of itch with cysteine protease inhibition |
IT1395963B1 (it) * | 2009-06-04 | 2012-11-02 | Rottapharm Spa | Forme cristalline di 6-(1h-imidazol-1-il)-2-fenil chinazolina e dei suoi sali |
TWI519533B (zh) | 2010-11-01 | 2016-02-01 | Lg生命科學有限公司 | 1-{(2S)-2-胺基-4-[2,4-雙(三氟甲基)-5,8-二氫吡啶并[3,4-d]嘧啶-7(6H)-基]-4-側氧丁基}-5,5-二氟哌啶-2-酮酒石酸鹽之水合物 |
EP2465498A1 (en) * | 2010-11-23 | 2012-06-20 | Faes Farma, S.A. | Diphenyl-amine derivatives: uses, process of synthesis and pharmaceutical compositions |
UY35370A (es) | 2013-03-06 | 2014-09-30 | Janssen Pharmaceutica Nv | Moduladores benzoimidazol-2-il pirimidina del receptor de histamina h4 |
-
2014
- 2014-03-06 UY UY0001035370A patent/UY35370A/es unknown
- 2014-03-06 HU HUE14760540A patent/HUE047681T2/hu unknown
- 2014-03-06 RS RS20200160A patent/RS59909B1/sr unknown
- 2014-03-06 BR BR112015021463A patent/BR112015021463A8/pt not_active Application Discontinuation
- 2014-03-06 TW TW103107723A patent/TWI617554B/zh not_active IP Right Cessation
- 2014-03-06 KR KR1020157026804A patent/KR102230383B1/ko active IP Right Grant
- 2014-03-06 AU AU2014225675A patent/AU2014225675B2/en not_active Ceased
- 2014-03-06 DK DK14760540.6T patent/DK2964229T3/da active
- 2014-03-06 MX MX2015011688A patent/MX2015011688A/es active IP Right Grant
- 2014-03-06 SG SG11201507117XA patent/SG11201507117XA/en unknown
- 2014-03-06 WO PCT/US2014/021130 patent/WO2014138368A1/en active Application Filing
- 2014-03-06 PT PT147605406T patent/PT2964229T/pt unknown
- 2014-03-06 NZ NZ710640A patent/NZ710640A/en not_active IP Right Cessation
- 2014-03-06 LT LTEP14760540.6T patent/LT2964229T/lt unknown
- 2014-03-06 JP JP2015561646A patent/JP6471103B2/ja not_active Expired - Fee Related
- 2014-03-06 MY MYPI2015702907A patent/MY180726A/en unknown
- 2014-03-06 EP EP19213615.8A patent/EP3660011A1/en not_active Withdrawn
- 2014-03-06 ES ES14760540T patent/ES2773543T3/es active Active
- 2014-03-06 CN CN201480012369.2A patent/CN105025898B/zh not_active Expired - Fee Related
- 2014-03-06 CA CA2903737A patent/CA2903737C/en active Active
- 2014-03-06 EA EA201591648A patent/EA201591648A1/ru unknown
- 2014-03-06 JO JOP/2014/0074A patent/JO3516B1/ar active
- 2014-03-06 PE PE2015001832A patent/PE20151536A1/es not_active Application Discontinuation
- 2014-03-06 SI SI201431440T patent/SI2964229T1/sl unknown
- 2014-03-06 US US14/199,634 patent/US8859575B2/en active Active
- 2014-03-06 EP EP14760540.6A patent/EP2964229B1/en active Active
- 2014-03-06 PL PL14760540T patent/PL2964229T3/pl unknown
- 2014-06-03 UA UAA201509634A patent/UA118754C2/uk unknown
- 2014-08-21 US US14/465,677 patent/US9278952B2/en not_active Expired - Fee Related
-
2015
- 2015-07-30 IL IL240247A patent/IL240247B/en active IP Right Grant
- 2015-08-06 PH PH12015501731A patent/PH12015501731A1/en unknown
- 2015-08-24 CR CR20150435A patent/CR20150435A/es unknown
- 2015-08-31 CL CL2015002434A patent/CL2015002434A1/es unknown
- 2015-09-02 GT GT201500243A patent/GT201500243A/es unknown
- 2015-09-03 SA SA515360981A patent/SA515360981B1/ar unknown
- 2015-10-05 ZA ZA2015/07351A patent/ZA201507351B/en unknown
-
2016
- 2016-01-22 DO DO2016000027A patent/DOP2016000027A/es unknown
- 2016-02-18 US US15/047,359 patent/US9434715B2/en active Active
- 2016-06-07 HK HK16106550.1A patent/HK1218513A1/zh unknown
- 2016-08-03 US US15/227,878 patent/US9663497B2/en active Active
-
2020
- 2020-02-03 CY CY20201100085T patent/CY1122545T1/el unknown
- 2020-02-14 HR HRP20200253TT patent/HRP20200253T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SA515360981B1 (ar) | مُعدِّلات بيريميدين بنزوإيميدازول-2-يل لمستقبِل الهستامين h4 | |
Wu et al. | School closure and mitigation of pandemic (H1N1) 2009, Hong Kong | |
Manchikanti et al. | Assessment of methodologic quality of randomized trials of interventional techniques: Development of an interventional pain management specific instrument | |
Shah et al. | Dental caries status of institutionalized orphan children from Jammu and Kashmir, India | |
BRPI1007018B8 (pt) | composto ligante de receptores de adenosina, composição farmacêutica, e, uso de um composto. | |
MX2012007273A (es) | Pteridinonas como inhibidores de la quinasa tipo polo. | |
Mohanta et al. | Dental fluorosis-revisited | |
Mposhi et al. | The importance of patenting traditional medicines in Africa: the case of Zimbabwe | |
Umeh et al. | Impact of the coronavirus disease 2019 pandemic on orthodontic patients and their attitude to orthodontic treatment | |
Dincer et al. | Bacterial biofilms | |
Al Kawas et al. | Post COVID-19 lockdown: measures and practices for dental institutes | |
Villarroel et al. | Health insurance continuity and health care access and utilization, 2014 | |
Moser et al. | Funding the costs of disease outbreaks caused by non-vaccination | |
Sanders et al. | The neoliberal roots of modern vaccine hesitancy | |
Yang et al. | Effect modification of environmental factors on influenza-associated mortality: a time-series study in two Chinese cities | |
CL2008001559A1 (es) | Compuestos heterociclos que contienen al menos un atomo de nitrogeno, moduladores de gamma secretasa; composiciones farmaceuticas que los comprenden; uso de los compuestos en la preparacion de medicamentos para tratar trastornos del sistema nervioso central, tal como alzheimer; y kit que incluye a la composicion farmaceutica. | |
Stoltzfus | Family first prevention services act (FFPSA) | |
Wegner-Lohin et al. | Ontario’s child welfare system | |
Jones et al. | Updated trends in child maltreatment, 2007. | |
Summer | Patenting Marijuana Strains: Baking Up Patent Protection for Growers in the Legal Fog of this Budding Industry | |
Arado et al. | Medical marijuana: an overview of select resources | |
Fowler | Written communication: from staff nurse to nurse consultant. Part 2: patient records. | |
Hibah | Extrapulmonary tuberculosis situation in El-Behira Governorate, Egypt | |
Richardson et al. | Probenecid in the treatment of neurosyphilis in men who have sex with men: a commentary | |
Sundriyal et al. | Multidermatomal herpes zoster |